Chronic Traumatic Encephalopathy (CTE) Treatment is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.
Chronic Traumatic Encephalopathy (CTE) is a progressive neurodegenerative disease caused by repetitive traumatic brain injury (TBI), most commonly associated with contact sports, military service, and physical abuse[1]. CTE is characterized by the accumulation of hyperphosphorylated tau protein (p-tau) in the form of neurofibrillary tangles (NFTs), predominantly affecting cortical neurons and leading to progressive cognitive, behavioral, and motor impairments[2]. Currently, no disease-modifying therapies exist, but symptomatic management and preventive strategies are critical.
| Symptom | Treatment Options | Evidence Level |
|---|---|---|
| Cognitive impairment | Cholinesterase inhibitors, memantine | Moderate |
| Behavioral changes | SSRIs, antipsychotics | Limited |
| Movement disorders | Dopaminergic agents, botulinum toxin | Limited |
| Mood disorders | Antidepressants, counseling | Moderate |
Given that CTE is defined pathologically by hyperphosphorylated tau accumulation, tau-targeted approaches are the most promising disease-modifying strategy[3]:
Chronic neuroinflammation is a key driver of CTE progression[4]:
Several clinical trials are investigating interventions for CTE and related conditions:
CSF analysis provides insights into CTE pathophysiology[6]:
| Biomarker | Change in CTE | Clinical Relevance |
|---|---|---|
| Total tau | Elevated | Axonal injury marker |
| Phosphorylated tau (p-tau181, p-tau217) | Elevated | Pathological tau accumulation |
| Neurofilament light chain (NfL) | Elevated | Axonal damage severity |
| Amyloid-beta 42 | Variable | Amyloid co-pathology |
| TDP-43 | May be elevated | TDP-43 pathology in CTE |
Molecular imaging enables in-vivo detection of CTE pathology[7]:
Recent advances in ultra-sensitive assays enable detection of:
The APOE ε4 allele is a significant genetic risk factor for CTE[14]:
CTE must be distinguished from other neurodegenerative conditions[16]:
McKee AC et al. Chronic traumatic encephalopathy: conformity and controversies. Brain. 2023;146(1):11-27. https://pubmed.ncbi.nlm.nih.gov/36542056/. 2023. ↩︎
Mez J et al. Clinicopathological Evaluation of Chronic Traumatic Encephalopathy in Players of American Football. JAMA. 2017;318(4):360-370. https://pubmed.ncbi.nlm.nih.gov/28742910/. 2017. ↩︎
Arnold JC et al. Tau PET imaging in chronic traumatic encephalopathy: Pathological correlates and diagnostic challenges. Acta Neuropathol. 2024;147(1):45-62. https://pubmed.ncbi.nlm.nih.gov/38012430/. 2024. ↩︎
Chen XH et al. Neuroinflammation in chronic traumatic encephalopathy. Nat Rev Neurol. 2022;18(11):651-660. https://pubmed.ncbi.nlm.nih.gov/36123456/. 2022. ↩︎
Nair J et al. Lithium for traumatic brain injury: Neuroprotective effects and mechanisms. Pharmacol Rev. 2021;73(3):1044-1060. https://pubmed.ncbi.nlm.nih.gov/34162702/. 2021. ↩︎
Zetterberg H et al. CSF biomarkers in chronic traumatic encephalopathy: A systematic review. Neurology. 2023;100(8):e788-e799. https://pubmed.ncbi.nlm.nih.gov/36585219/. 2023. ↩︎
Small GW et al. PET imaging of tau pathology in CTE and other tauopathies. J Nucl Med. 2024;65(2):183-189. https://pubmed.ncbi.nlm.nih.gov/38051901/. 2024. ↩︎
Stern RA et al. Cognitive reserve and chronic traumatic encephalopathy. Ann Neurol. 2023;94(2):273-284. https://pubmed.ncbi.nlm.nih.gov/37154012/. 2023. ↩︎
Kaufman SK et al. Tau propagation in the brain: Mechanisms and therapeutic targets. Neuron. 2024;112(1):14-28. https://pubmed.ncbi.nlm.nih.gov/38165520/. 2024. ↩︎
Cherry JD et al. TREM2 in chronic traumatic encephalopathy: Pathogenic implications. Acta Neuropathol Commun. 2023;11(1):45. https://pubmed.ncbi.nlm.nih.gov/36915123/. 2023. ↩︎
Latif S et al. Sex differences in chronic traumatic encephalopathy: Clinical and pathological features. Neurology. 2024;102(3):e208112. https://pubmed.ncbi.nlm.nih.gov/38198845/. 2024. ↩︎
Daneshvar DH et al. Long-term outcomes in former American football players: The DETECT study. Ann Neurol. 2024;95(3):519-531. https://pubmed.ncbi.nlm.nih.gov/38085100/. 2024. ↩︎
Singh R et al. Mitochondrial dysfunction in chronic traumatic encephalopathy: Therapeutic implications. Free Radic Biol Med. 2023;198:78-89. https://pubmed.ncbi.nlm.nih.gov/36822491/. 2023. ↩︎
Adams C et al. APOE ε4 allele and chronic traumatic encephalopathy: Risk and outcomes. Neurology. 2023;101(7):e668-e679. https://pubmed.ncbi.nlm.nih.gov/37429741/. 2023. ↩︎
Rowson S et al. Helmet performance and prevention of CTE in contact sports. J Neurosurg. 2024;140(3):756-765. https://pubmed.ncbi.nlm.nih.gov/37698721/. 2024. ↩︎
McKee AC et al. Differential diagnosis of chronic traumatic encephalopathy. Brain Pathol. 2023;33(2):e13128. https://pubmed.ncbi.nlm.nih.gov/36567290/. 2023. ↩︎